title: [Novel treatment options in relapsed and refracter Hodgkin lymphomas].
abstract: BACKGROUND
  Hodgkin lymphoma is a curable lymphoma with an 80-90% long-term survival, however, 30% of the patients develop relapse. Only half of relapsed patients can be cured with autologous stem cell transplantation.
  
  
  OBJECTIVE
  The aim of the authors was to analyze survival rates and incidence of relapses among Hodgkin lymphoma patients who were treated between January 1, 1980 and December 31, 2014. Novel therapeutic options are also summarized.
  
  
  METHODS
  Retrospective analysis of data was performed.
  
  
  RESULTS
  A total of 715 patients were treated (382 men and 333 women; median age at the time of diagnosis was 38 years). During the studied period the frequency of relapsed patients was reduced from 24.87% to 8.04%. The numbers of autologous stem cell transplantations was increased among refracter/relapsed patients, and 75% of the patients underwent transplantation since 2000. The 5-year overall survival improved significantly (between 1980 and 1989 64.4%, between 1990 and 1999 82.4%, between 2000 and 2009 88.4%, and between 2010 and 2014 87.1%). Relapse-free survival did not change significantly.
  
  
  CONCLUSIONS
  During the study period treatment outcomes improved. For relapsed/refractory Hodgkin lymphoma patients novel treatment options may offer better chance for cure.
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors.forename: Árpád
authors.initials: Á
authors.lastname: Illés
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors.forename: Ádám
authors.initials: Á
authors.lastname: Jóna
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Simon
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors.forename: Miklós
authors.initials: M
authors.lastname: Udvardy
authors.affiliation: Belgyógyászati Intézet, Hematológiai Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar Debrecen.
authors.forename: Zsófia
authors.initials: Z
authors.lastname: Miltényi
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000187:drug effects / Q000378:metabolism; D000069461:Bendamustine Hydrochloride / Q000008:administration & dosage; D000079963:Brentuximab Vedotin; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006689:Hodgkin Disease / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D018796:Immunoconjugates / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology* / Q000401:mortality / Q000628:therapy*; D012008:Recurrence; D012189:Retrospective Studies; D000069283:Rituximab / Q000008:administration & dosage; D016879:Salvage Therapy / Q000379:methods; D012598:Sclerosis; D016019:Survival Analysis; D015996:Survival Rate; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D060890:B7-H1 Antigen; C423236:CD274 protein, human; D018796:Immunoconjugates; D000069283:Rituximab; D000079963:Brentuximab Vedotin; D000069461:Bendamustine Hydrochloride
keywords: Hodgkin lymphoma; Hodgkin-lymphoma; kezelés; refractory; refrakter; relapse; relapsus; treatment